126 related articles for article (PubMed ID: 34825792)
21. Effects of risk factors for ovarian cancer in women with and without endometriosis.
Phung MT; Muthukumar A; Trabert B; Webb PM; Jordan SJ; Terry KL; Cramer DW; Titus LJ; Risch HA; Doherty JA; Harris HR; Goodman MT; Modugno F; Moysich KB; Jensen A; Kjaer SK; Anton-Culver H; Ziogas A; Berchuck A; Khoja L; Wu AH; Pike MC; Pearce CL; Lee AW
Fertil Steril; 2022 Nov; 118(5):960-969. PubMed ID: 36182623
[TBL] [Abstract][Full Text] [Related]
22. Letter to the Editor: Fletcher NM, Harper AK, Memaj I, Fan R, Morris RT, Saed GM. Molecular Basis Supporting the Association of Talcum Powder Use with Increased Risk of Ovarian Cancer. Reprod Sci. 2019;26(12):1603-12. DOI: 10.1177/1933719119831773.
Mossman BT
Reprod Sci; 2020 Oct; 27(10):1834-1835. PubMed ID: 32813197
[No Abstract] [Full Text] [Related]
23. Talc powder and ovarian cancer: what is the evidence?
Micha JP; Rettenmaier MA; Bohart R; Goldstein BH
Arch Gynecol Obstet; 2022 Oct; 306(4):931-933. PubMed ID: 35348830
[TBL] [Abstract][Full Text] [Related]
24. Potential Airborne Asbestos Exposure and Risk Associated with the Historical Use of Cosmetic Talcum Powder Products.
Burns AM; Barlow CA; Banducci AM; Unice KM; Sahmel J
Risk Anal; 2019 Oct; 39(10):2272-2294. PubMed ID: 30980426
[TBL] [Abstract][Full Text] [Related]
25. "Nondetected": The Politics of Measurement of Asbestos in Talc, 1971-1976.
Rosner D; Markowitz G; Chowkwanyun M
Am J Public Health; 2019 Jul; 109(7):969-974. PubMed ID: 31095409
[TBL] [Abstract][Full Text] [Related]
26. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.
Gates MA; Tworoger SS; Terry KL; Titus-Ernstoff L; Rosner B; De Vivo I; Cramer DW; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2436-44. PubMed ID: 18768514
[TBL] [Abstract][Full Text] [Related]
27. Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.
Terry KL; Karageorgi S; Shvetsov YB; Merritt MA; Lurie G; Thompson PJ; Carney ME; Weber RP; Akushevich L; Lo-Ciganic WH; Cushing-Haugen K; Sieh W; Moysich K; Doherty JA; Nagle CM; Berchuck A; Pearce CL; Pike M; Ness RB; Webb PM; ; ; Rossing MA; Schildkraut J; Risch H; Goodman MT;
Cancer Prev Res (Phila); 2013 Aug; 6(8):811-21. PubMed ID: 23761272
[TBL] [Abstract][Full Text] [Related]
28. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
29. Perineal powder use and risk of ovarian cancer.
Houghton SC; Reeves KW; Hankinson SE; Crawford L; Lane D; Wactawski-Wende J; Thomson CA; Ockene JK; Sturgeon SR
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214560
[TBL] [Abstract][Full Text] [Related]
30. Perineal exposure to talc and ovarian cancer risk.
Harlow BL; Cramer DW; Bell DA; Welch WR
Obstet Gynecol; 1992 Jul; 80(1):19-26. PubMed ID: 1603491
[TBL] [Abstract][Full Text] [Related]
31. Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer.
Sakai K; Kaku T; Kamura T; Kinukawa N; Amada S; Shigematsu T; Hirakawa T; Kobayashi H; Ariyoshi K; Nakano H
Gynecol Oncol; 1999 Mar; 72(3):360-6. PubMed ID: 10053108
[TBL] [Abstract][Full Text] [Related]
32. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
33. Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
Wentzensen N; O'Brien KM
Gynecol Oncol; 2021 Oct; 163(1):199-208. PubMed ID: 34366148
[TBL] [Abstract][Full Text] [Related]
34. Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium.
Davis CP; Bandera EV; Bethea TN; Camacho F; Joslin CE; Wu AH; Beeghly-Fadiel A; Moorman PG; Myers ER; Ochs-Balcom HM; Peres LC; Rosenow WT; Setiawan VW; Rosenberg L; Schildkraut JM; Harris HR
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1660-1668. PubMed ID: 34155063
[TBL] [Abstract][Full Text] [Related]
35. Pycnogenol reduces talc-induced neoplastic transformation in human ovarian cell cultures.
Buz'Zard AR; Lau BH
Phytother Res; 2007 Jun; 21(6):579-86. PubMed ID: 17357971
[TBL] [Abstract][Full Text] [Related]
36. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies.
Huncharek M; Geschwind JF; Kupelnick B
Anticancer Res; 2003; 23(2C):1955-60. PubMed ID: 12820486
[TBL] [Abstract][Full Text] [Related]
37. [Expression of p53 and Ki-67 genes in epithelial dysplasia from old oral mucosa and clinical significance].
Zhao J; Guo B; Ma SC; Zhou XD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Sep; 36(5):689-91. PubMed ID: 16235539
[TBL] [Abstract][Full Text] [Related]
38. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry.
Henriksen R; Strang P; Wilander E; Bäckström T; Tribukait B; Oberg K
Gynecol Oncol; 1994 Jun; 53(3):301-6. PubMed ID: 8206402
[TBL] [Abstract][Full Text] [Related]
39. Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
Anton A; Schott S; Kaip G; Rath M; Heil J; Aulmann S; Sinn HP
Arch Gynecol Obstet; 2014 May; 289(5):1079-85. PubMed ID: 24196303
[TBL] [Abstract][Full Text] [Related]
40. Perineal powder exposure and the risk of ovarian cancer.
Cook LS; Kamb ML; Weiss NS
Am J Epidemiol; 1997 Mar; 145(5):459-65. PubMed ID: 9048520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
